Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.

Fiche publication

Date publication

août 2024

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Pr COUTANT Charles , Dr DABAKUYO-YONLI Sandrine , Dr LADOIRE Sylvain , Mme TRUNTZER Caroline , Dr NAMBOT Sophie , Dr DESMOULINS Isabelle , Dr HENNEQUIN Audrey , Dr MAMGUEM KAMGA Ariane , Dr MAYEUR Didier , Dr GALLAND Loïck , Dr REDA Manon , Dr ALBUISSON Juliette

Tous les auteurs :
Ladoire S, Mamguem Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie SM, Hennequin A, Jankowski C, Albuisson J, Nambot S, Coutant C, Arnould L, Reda M, Truntzer C, Dabakuyo S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39243563

Résumé

The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse in patients with a germline BRCA1/2 mutation (gBRCAm). However, the proportion of patients in routine practice who meet the "high-risk" criteria applied in the OlympiA study, and for whom gBRCAm testing would now be mandatory, remains unknown.